Quince Therapeutics, Inc. — Company profile
United States
Last price 31.62 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 32.16M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells and consists of automated equipment, the RCL, a sterile single-use consumable treatment kit comprising medical device kits, syringe kits, and process solutions. IRulya Therapeutics Inc. was formerly known as Quince Therapeutics, Inc. and changed its name to IRulya Therapeutics Inc. in October 2026. The company was incorporated in 2012 and is headquartered in New Haven, Connecticut.
Details
| Name | IRulya Therapeutics Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 38 |
| Founded | 2012 |
| Ipo Date | 2019-05-09 |
| Ceo | Brigette Roberts |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US22053A3059 |
| Cusip | 22053A305 |
| Cik | 0001662774 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Brigette Roberts M.D. | Chief Executive Officer, Principal Executive Officer and Director |
| Dr. Keith R. Fandrick Ph.D. | Chief Operating Officer |
| Dr. Guenter R. Janhofer M.D., Ph.D. | Chief Scientific Officer |
Contact
| Address | 101 College Street, Suite 210, New Haven, Connecticut 06510, United States |
| Website | https://irulya.com |